Fibrocystic Breast Changes
Benign cyclic breast lumpiness and tenderness — extremely common; reassurance after exclusion of malignancy.
Also known as: fibrocystic breast disease, fibrocystic changes, breast cysts, benign breast disease
Overview
Constellation of benign, hormonally responsive changes in the breast — stromal fibrosis, cyst formation, ductal hyperplasia, and apocrine metaplasia — producing nodularity and cyclic discomfort. No longer considered a 'disease.'
Epidemiology
Most common benign breast condition; affects ~50-60% of reproductive-age women. Peak incidence ages 30-50. Usually subsides after menopause unless on hormone therapy.
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Fibrocystic Breast Changes outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Risk factors
- Age 30-50 (reproductive years)
- Estrogen-progesterone imbalance
- Hormone therapy
- Caffeine and methylxanthine intake (controversial)
- Family history
Pathophysiology
Exaggerated cyclic response to ovarian estrogen and progesterone produces stromal proliferation, lobular hyperplasia, and accumulation of fluid in obstructed terminal ductal lobular units → microcyst and macrocyst formation. Most lesions confer no increased cancer risk; atypical hyperplasia (atypical ductal or lobular hyperplasia) does (~4-5x).
Clinical presentation
Symptoms
- Bilateral diffuse breast lumpiness, often most prominent in upper outer quadrants
- Cyclic breast pain (mastalgia) worse premenstrually, relieved with menses
- Palpable cysts that may fluctuate in size with cycle
- Generally NOT associated with bloody nipple discharge
Signs / physical exam
- Diffuse nodularity, 'cobblestone' texture
- Tender areas, especially premenstrually
- Discrete cysts may be palpable
- No skin or nipple changes; no lymphadenopathy
Differential diagnosis
- Breast cancer — Persistent, fixed, irregular mass with skin/nipple changes; imaging and biopsy
- Fibroadenoma — Discrete mobile rubbery mass in younger women; well-circumscribed on ultrasound
- Simple cyst — Round, anechoic on ultrasound; can aspirate
- Mastitis / abscess — Warm, erythematous, tender; fever; lactation or recent skin breach
- Phyllodes tumor — Rapidly growing firm mass; benign-to-malignant spectrum
- Fat necrosis — Trauma or surgery history
Diagnostic workup
Imaging
- Clinical breast exam at multiple cycle points to distinguish cyclic changes from persistent mass
- Ultrasound — first-line for women <30 or pregnant; characterizes cysts (anechoic, posterior enhancement)
- Mammography — for women ≥30 with palpable mass
- Cyst aspiration if symptomatic, complex, or BI-RADS 4: clear/yellow/green/brown fluid → discard; bloody fluid → send for cytology and biopsy wall
- Core needle biopsy for solid lesions or recurrent/complex cysts
Diagnostic algorithm
| Feature | Fibrocystic Changes | Fibroadenoma | Breast Cyst | Breast Cancer |
|---|---|---|---|---|
| Age | 30-50 | 15-35 | 35-50 | >40 (usually) |
| Number / laterality | Multiple, bilateral | Single (sometimes multiple) | Single or multiple | Usually single |
| Texture | Lumpy, nodular | Firm, rubbery, mobile | Smooth, fluctuant | Hard, fixed, irregular |
| Cyclic change | Yes (tender premenstrually) | Minimal | Mild | No |
| Imaging | Heterogeneous, cysts | Well-circumscribed solid | Anechoic, posterior enhancement | Spiculated mass, calcifications |
| Management | Reassurance, supportive | Observation or excision | Aspiration if symptomatic | Biopsy → oncologic treatment |
Treatment
First-line
- Reassurance after exclusion of malignancy
- Supportive measures: well-fitted supportive bra, warm/cool compresses
- NSAIDs (oral or topical diclofenac) for mastalgia
- Reduction in caffeine, dietary fat (modest, inconsistent evidence)
Second-line / adjunct
- Combined OCP — reduces cyclical pain in some patients
- Tamoxifen 10 mg/day or danazol — refractory severe mastalgia; off-label, significant side effects
- Evening primrose oil — modest evidence, low risk
- Cyst aspiration for symptomatic relief
Complications
- Patient anxiety from frequent self-detected lumps
- Recurrent cyst formation
- Coexistence with malignancy (changes do not protect against cancer)
- Atypical hyperplasia subset confers increased breast cancer risk (~4x)
PANCE pearls
- Fibrocystic changes themselves do NOT increase breast cancer risk unless histology reveals proliferative changes with atypia.
- Cyst aspiration is both diagnostic and therapeutic — clear fluid that does not recur requires no further workup.
- Bloody fluid from a cyst, residual mass after aspiration, or rapid recurrence → biopsy.
- Cyclic mastalgia is much more common than continuous mastalgia; the latter warrants more thorough evaluation.
- Reassure patients that lumpiness varies with cycle — best to re-examine in days 5-10 of cycle when changes are minimal.
References
- ACOG CO 821 — ACOG Committee Opinion 821: Benign Breast Conditions and Management
- ASBrS 2019 — American Society of Breast Surgeons Consensus Guideline on Diagnosis and Management of Cystic Breast Lesions
Practice Reproductive questions on FirstPassPA
Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Browse all 514 diagnosesEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.